QSAM Biosciences Receives Second Key Patent in Europe for its Clinical Stage Radiopharmaceutical Drug Candidate, CycloSam®

Stock Information for Telix QSAM Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Telix QSAM Inc.

QSAM ANNOUNCES REVERSE STOCK SPLIT RATIO AHEAD OF MERGER
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of QSAM Biosciences, Inc. (QSAM)
QSAM Biosciences Signs Definitive Agreement to be Acquired by Telix Pharmaceuticals
QSAM Biosciences Signs Term Sheet to be Acquired by Telix Pharmaceuticals; Receives $2 Million Pre-Closing Collaboration and Option Fee
QSAM Biosciences Provides Update to Shareholders on Phase 1 Progress and Preliminary Clinical Data
QSAM Biosciences Adds the Nuclear Reactor at the University of Texas at Austin to its Radioisotope Production Supply Chain for its Bone Cancer Treatment Drug Candidate, CycloSam®
QSAM Biosciences Expands its Study of CycloSam® in the Treatment of Bone Cancer; Opens Patient Enrollment at Key Chicago Center, Insight Hospital and Medical Center
QSAM Biosciences and RLS Announce Clinical and Commercial Supply Agreement for Promising Clinical-Stage Metastatic and Primary Bone Cancer Treatment, CycloSam®

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.